0001610717-24-000053.txt : 20240212
0001610717-24-000053.hdr.sgml : 20240212
20240212162758
ACCESSION NUMBER: 0001610717-24-000053
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240208
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hata Yujiro S
CENTRAL INDEX KEY: 0001649119
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 24620394
MAIL ADDRESS:
STREET 1: C/O XENCOR, INC.
STREET 2: 111 WEST LEMON AVENUE
CITY: MONROVIA
STATE: CA
ZIP: 91016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
form4.xml
X0508
4
2024-02-08
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001649119
Hata Yujiro S
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
true
true
President and CEO
true
Common Stock
2024-02-08
4
M
0
75815
4.31
A
753702
D
Common Stock
2024-02-08
4
S
0
75815
45.1472
D
677887
D
Common Stock
2024-02-09
4
M
0
23557
4.31
A
701444
D
Common Stock
2024-02-09
4
S
0
23557
45.537
D
677887
D
Stock Option (right to buy)
4.31
2024-02-08
4
M
0
75815
0
D
2028-02-26
Common Stock
75815
248011
D
Stock Option (right to buy)
4.31
2024-02-09
4
M
0
23557
0
D
2028-02-26
Common Stock
23557
224454
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023.
This transaction was executed in multiple trades in prices ranging from $45.00 to $45.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $45.01 to $45.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares subject to the option are fully vested and exercisable.
/s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata
2024-02-12